Your session is about to expire
← Back to Search
Part B - LT3001 and Aspirin for Stroke
Phase 1
Waitlist Available
Research Sponsored by Lumosa Therapeutics Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 days
Awards & highlights
Summary
This trial tests a new drug, LT3001, in healthy people to see if it's safe and how it behaves in the body. It also checks if LT3001 interacts with common medications like aspirin and blood thinners.
Eligible Conditions
- Stroke
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 16 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of adverse events
Secondary study objectives
Changes from baseline in coagulation
Changes from baseline in platelet function test
Plasma PK parameters of Apixaban - AUC
+14 moreTrial Design
6Treatment groups
Experimental Treatment
Placebo Group
Group I: Part B - LT3001 and DabigatranExperimental Treatment2 Interventions
Multiple doses of LT3001 and Dabigatran administered
Group II: Part B - LT3001 and ClopidogrelExperimental Treatment2 Interventions
Multiple doses of LT3001 and Clopidogrel administered
Group III: Part B - LT3001 and AspirinExperimental Treatment2 Interventions
Multiple doses of LT3001 and Aspirin administered
Group IV: Part B - LT3001 and ApixabanExperimental Treatment2 Interventions
Multiple doses of LT3001 and Apixaban administered
Group V: Part A - LT3001 Drug ProductExperimental Treatment1 Intervention
Multiple doses of LT3001 administered by intravenous infusion
Group VI: Part A - PlaceboPlacebo Group1 Intervention
Multiple doses of Placebo administered by intravenous infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dabigatran
FDA approved
Acetylsalicylic acid
FDA approved
Apixaban
FDA approved
Clopidogrel
FDA approved
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Lumosa Therapeutics Co., Ltd.Lead Sponsor
7 Previous Clinical Trials
625 Total Patients Enrolled
Mimi Yeh, PhDStudy DirectorLumosa Phase 1 unit
Share this study with friends
Copy Link
Messenger